Should I buy Imugene stock in 2025?

Why trust HelloSafe ?

At HelloSafe, our expert has been tracking Imugene's performance for over three years. Every month, hundreds of thousands of users in Australia trust us to analyse market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, compensated by Imugene.

What is Imugene?

The Imugene stock price

The price of Imugene stock is declining this week. The current share price is $0.014 AUD, unchanged over the last 24 hours but down 15.38% for the week. Imugene’s market capitalisation stands at $93.47 million AUD, with an average 3-month daily trading volume of about 583,333 shares. The P/E ratio is not applicable due to operating losses, while the dividend yield remains 0%. With a beta of 3.39, Imugene is highly volatile—suited to investors seeking exposure to speculative biotech opportunities.

Our full analysis of the Imugene stock

We have thoroughly examined Imugene’s most recent financial disclosures and tracked its stock performance over the past three years. By integrating a combination of financial data, technical signals, market developments, and competitive insights through our proprietary analytical algorithms, we can now present a comprehensive view of this biotech innovator’s standing. So, why might Imugene stock once again become a strategic entry point into the innovative healthcare and immuno-oncology sector in 2025?

Recent performance and market context

Imugene’s share price stands at $0.014 AUD as of July 2025, reflecting an extremely volatile year marked by a substantial share price decline of 99.19% over the trailing twelve months. Despite this, the stock has remained actively traded, with an average daily volume of approximately 583,333 shares and a current market capitalisation of $93.47 million AUD. The company recently achieved several noteworthy milestones: the dosing of its first patient in a Phase II trial of PD1-Vaxx, a US patent win for onCARlytics, and MAST trial patients showing durable remission on VAXINIA. These developments have been seen as promising, especially when contextualised with broader sector tailwinds—Australian biotech and life sciences are entering an era of strong policy support, active international capital flows, and a robust pipeline of clinical-stage assets. The prudence of investors remains high in speculative sectors, yet renewed optimism is emerging around innovative firms with tangible progress and scalable scientific platforms.

Technical analysis

Technical indicators for Imugene suggest that the stock may be forming a structural base for a potential recovery. The RSI sits at 39.22, which is on the lower end of the range and often considered oversold or neutral, presenting an interesting potential for reversal. The MACD remains negative (-0.05), typically interpreted as a bearish short-term signal, yet the clustering near a key support at $0.012 AUD (52-week low) hints at stabilisation as selling momentum wanes. All medium- and long-term moving averages (20, 50, 200 days) remain well above the current share price, reflecting a period of sustained weakness but also suggesting substantial upside if sentiment or catalysts shift. In high beta, early-stage biotech names, such sharp dislocations can create asymmetric opportunities for investors willing to position ahead of inflection points—especially given the strong technical boundary defined by support and the potential resistance set by the prior high at $2.754 AUD.

Fundamental analysis

Imugene’s fundamental story is anchored in innovation and a high-impact clinical development pipeline. The business operates with a focused model: advancing a diversified suite of cancer immunotherapies and targeted viral and cell-based treatments. Current financials show negative revenue (-$1.84 million AUD TTM) and a reported EBITDA of -$116.82 million AUD, which are common in clinical-stage biotechs investing heavily in R&D to achieve regulatory and clinical milestones. Imugene’s net loss of $129.3 million AUD reflects aggressive investment in advancing its six proprietary therapeutic assets, including Phase II progression for PD1-Vaxx and first-in-class treatments such as VAXINIA (oncolytic virus) and azer-cel (allogeneic CAR-T). While the stock currently trades on no earnings and therefore lacks a meaningful P/E ratio, its potential is underpinned by the size and quality of its drug candidate portfolio and the tangible proof points delivered by recent trial readouts. In biotechs, inflection often comes not from near-term financials, but from progress in clinical milestones and IP expansion—both areas where Imugene has made notable advances.

Volume and liquidity

Despite recent price pressure, Imugene maintains a consistent level of market liquidity, making it more accessible for both retail and institutional participants. The 3-month average daily trading volume of over half a million shares, paired with a large outstanding float (7.47 billion shares, with 187.83 million publicly available for trading), supports price discovery and makes entry and exit efficient even during volatile periods. This liquidity profile, atypical for smaller cap biotechs, enables dynamic valuation as news and sentiment evolve—valuable characteristics for those seeking exposure to catalysts or market momentum. When trading volumes remain stable even after significant price drawdowns, it often signals that market participants are closely tracking the next positive catalyst.

Catalysts and positive outlook

• Advancing Clinical Trials: Phase II development of PD1-Vaxx in Australia and global markets positions Imugene at the forefront of next-generation immunotherapy.
• Pipeline Momentum: Ongoing trials for MAST with VAXINIA and early-stage progress with azer-cel (allogeneic CAR-T therapy) highlight the company’s multi-pronged approach to treating solid and haematological tumours.
• Intellectual Property Expansion: Recent US patent approval for onCARlytics enhances Imugene's competitive moat, increasing commercialisation prospects and partnering opportunities.
• Regulatory Potential: Anticipated regulatory and clinical trial milestones in 2025-2026 could transform valuation multiples, as seen with successful biotechs globally.
• Growing Biotech Sector Support: Australia’s renewed focus on biotech commercialisation, capital incentives, and support for local clinical innovation create fertile ground for sector leaders.
• Market Sentiment: Broker consensus price target of $0.40 AUD underlines the perceived potential upside, reflecting possible multiples of the current price.

Imugene’s rapidly advancing pipeline and intellectual property momentum offer attractive leverage to sector breakthroughs or licensing/partnership deals.

Investment strategies

• Short-term positioning: The stock hovers near a major technical support at $0.012 AUD, potentially setting up for a short-term rebound on any positive clinical data or partnership news.
• Medium-term strategy: Participation ahead of key clinical results or regulatory milestones may be warranted, capturing upside from successful trial readouts or commercialisation news.
• Long-term allocation: For investors focused on disruptive biotech innovation and willing to absorb volatility for upside optionality, accumulating a starter position at or near historical lows—particularly given the robust clinical pipeline—presents compelling asymmetry. Averaging in, rather than lump-sum allocations, helps manage risk in early-stage healthcare names.

Portfolio allocation to Imugene at this juncture should be considered within the context of sector exposure, risk appetite, and investment horizon. High volatility, as demonstrated by a 1-year beta of 3.39, should be balanced by a view to the outsized rewards of transformative biotech innovation.

Is it the right time to buy Imugene?

In conclusion, Imugene distinguishes itself with an exceptional and diversified pipeline of immuno-oncology therapies, ambitious clinical programs, and expanding intellectual property. The aftermath of a severe share price reset, while undoubtedly challenging, opens a new window for investors to gain leveraged exposure to high-impact milestones at a deep discount to historic peaks. Recent operational and clinical achievements justify renewed optimism in the stock’s outlook, particularly for those comfortable with volatility and who can appreciate the inflection potential of successful biotech investments.

Imugene seems to represent an excellent opportunity for strategic investors seeking exposure to early-stage biotech with outsized potential. The fundamentals, technical base, and imminent clinical catalysts all suggest the stock may be entering a new bullish phase, well positioned for strong recovery as the pipeline delivers. For those with conviction in Australian healthcare innovation and an appetite for risk-managed opportunity, Imugene could be a rewarding addition as sector momentum builds through 2025.

How to buy Imugene stock in Australia

Buying Imugene stock online is straightforward and secure when you use a regulated Australian broker. You can choose between a standard spot (cash) purchase, making you an actual shareholder, or trading via CFDs (contracts for difference) to speculate with leverage. Each method is suitable for different investor needs and goals. If you want to compare brokers’ fees and features, a dedicated comparison can be found further down this page.

Spot buying

Cash buying means purchasing Imugene shares outright on the ASX, giving you full legal ownership and eligibility for future dividends. Australian brokers usually charge a modest fixed commission per order, typically around $5 to $10. This method lets you directly benefit from any price appreciation.

Gain scenario

If the Imugene share price is $0.014 AUD, you can buy about 71,425 shares with a $1,000 stake, including a brokerage fee of about $5.

If the share price rises by 10%, your shares are now worth $1,100.

Result: +$100 gross gain, i.e. +10% on your investment.

Trading via CFD

CFD trading on Imugene lets you speculate on price movements without actually owning the shares. CFDs enable the use of leverage—commonly 2x to 5x—so you can amplify gains (and losses). Fees generally consist of a bid-ask spread, plus possible overnight financing charges if your position is held longer than a day.

Example of a CFD position with leverage

You open a CFD position on Imugene shares, with 5x leverage. This gives you a market exposure of $5,000.

✔️ Gain scenario:
If the stock rises by 8%, your position gains 8% × 5 = 40%.
Result: +$400 gain, on a bet of $1,000 (excluding fees).

Final advice

Before you invest in Imugene, carefully compare the fees, features, and regulatory settings of each broker—some favour low-cost cash trades, while others offer competitive CFD options. The right choice depends on your investment goals, time horizon, and approach to risk. For more details, see the comprehensive broker comparison table on this page.

Our 7 tips for buying Imugene stock

The latest news about Imugene

Imugene dosed its first Australian patient in a Phase II PD1-Vaxx clinical trial this past week. This major development demonstrates Imugene’s operational progress and leadership in the local immuno-oncology sector, directly benefiting Australian research infrastructure and reaffirming the company’s commitment to domestic clinical advancement.

Imugene secured a new US patent for its onCARlytics immunotherapy platform in late June 2025. This achievement enhances Imugene’s global intellectual property portfolio and opens pathways for cross-border collaboration, while reinforcing the value of its locally developed innovations for potential licensing and commercialisation.

Consensus analyst price target remains significantly above the current valuation, indicating strong upside potential. Current market consensus sets a target of 0.40 AUD per share versus the prevailing 0.014 AUD price. This wide gap is grounded in the anticipated milestones for Imugene’s clinical programs and ongoing investor interest in Australian biotechnology breakthroughs.

Positive long-term clinical data were reported from the VAXINIA MAST trial, supporting future regulatory submissions. The study, which included Australian patients, highlighted a full remission spanning over two years for one participant, substantiating the effectiveness of the platform and supporting optimism for future therapeutic approvals.

Imugene continues to benefit from its Sydney headquarters and diversified ASX investor base. The company’s strong domestic presence allows it to draw on Australian research talent and biotech funding ecosystems, maintaining close ties with local institutional investors and contributing to national sector leadership.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.